TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Double-Blind, Multicenter, Dose-Ranging, Crossover Study to Evaluate the Safety and Efficacy of Subcutaneous Administration of CINRYZE® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20) for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Brief Summary: The primary objectives of the study are to evaluate the safety, tolerability, and efficacy of two doses of CINRYZE with recombinant human hyaluronidase (rHuPH20) administered by subcutaneous (SC) injection to prevent angioedema attacks.


Options:
A: Arm Label: Open-label C1INH-nf; Type: EXPERIMENTAL; Interventions: Biological: C1 esterase inhibitor [human] (C1INH-nf) | Intervention Type: BIOLOGICAL; Name: C1 esterase inhibitor [human] (C1INH-nf); Assigned to Arm(s): Open-label C1INH-nf
B: Arm Label: C1INH-nf; Type: EXPERIMENTAL; Interventions: Biological: C1 esterase inhibitor [human] (C1INH-nf) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (saline) | Intervention Type: BIOLOGICAL; Name: C1 esterase inhibitor [human] (C1INH-nf); Assigned to Arm(s): C1INH-nf | Intervention Type: DRUG; Name: Placebo (saline); Assigned to Arm(s): Placebo
C: Arm Label: SC CINRYZE with rHuPH20 Dose Level 1 followed by Dose Level 2; Type: EXPERIMENTAL; Interventions: Biological: CINRYZE with rHuPH20 | Arm Label: SC CINRYZE with rHuPH20 Dose Level 2 followed by Dose Level 1; Type: EXPERIMENTAL; Interventions: Biological: CINRYZE with rHuPH20 | Intervention Type: BIOLOGICAL; Name: CINRYZE with rHuPH20; Assigned to Arm(s): SC CINRYZE with rHuPH20 Dose Level 1 followed by Dose Level 2, SC CINRYZE with rHuPH20 Dose Level 2 followed by Dose Level 1
D: Arm Label: Part 1: BCX7353 350 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: BCX7353 | Arm Label: Parts 2 and 3: BCX7353 250 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: BCX7353 | Arm Label: Parts 2 and 3: BCX7353 125 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: BCX7353 | Arm Label: Parts 1, 2 and 3: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 3: BCX7353 62.5 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: BCX7353 | Intervention Type: DRUG; Name: BCX7353; Assigned to Arm(s): Part 1: BCX7353 350 mg once daily, Part 3: BCX7353 62.5 mg once daily, Parts 2 and 3: BCX7353 125 mg once daily, Parts 2 and 3: BCX7353 250 mg once daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Parts 1, 2 and 3: Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Alcohol Harm Reduction Intervention Among Female Sex Workers in Mombasa, Kenya
Brief Summary: The main study objective is to investigate whether female sex workers (FSWs) at drop-in centers in Mombasa, Kenya, who report harmful or hazardous alcohol intake and participate in a brief alcohol intervention (vs. those who participate in a nutrition intervention in the control group), will reduce their alcohol use and incidence of STIs, HIV, and sexual violence, as well as increase their condom use.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Counseling Intervention (BCI) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: BCI + Naltrexone | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Brief Counseling Intervention (BCI); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: BCI + Naltrexone; Assigned to Arm(s): 3 | Intervention Type: BEHAVIORAL; Name: Treatment as Usual; Assigned to Arm(s): 4
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Intervention for Alcohol Use | Intervention Type: BEHAVIORAL; Name: Behavioral Intervention for Alcohol Use; Assigned to Arm(s): Intervention
C: Arm Label: Mentor Mothers Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Peer support and mentoring | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Peer support and mentoring; Assigned to Arm(s): Mentor Mothers Intervention
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Escalating incentives (EtG tests); Type: EXPERIMENTAL; Interventions: Behavioral: Incentives for negative EtG test | Arm Label: Escalating incentives (IsoScreen tests); Type: EXPERIMENTAL; Interventions: Behavioral: Incentives for positive IsoScreen test | Arm Label: Escalating incentives (EtG + IsoScreen); Type: EXPERIMENTAL; Interventions: Behavioral: Incentives for negative EtG test, Behavioral: Incentives for positive IsoScreen test | Intervention Type: BEHAVIORAL; Name: Incentives for negative EtG test; Assigned to Arm(s): Escalating incentives (EtG + IsoScreen), Escalating incentives (EtG tests) | Intervention Type: BEHAVIORAL; Name: Incentives for positive IsoScreen test; Assigned to Arm(s): Escalating incentives (EtG + IsoScreen), Escalating incentives (IsoScreen tests)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Safety and Feasibility of Administering Xenon to Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery: a Pilot Study
Brief Summary: Purpose of this study is to test whether xenon application during off-pump-coronary artery bypass (OPCAB)-surgery is safe and feasible.


Options:
A: Arm Label: RIPC; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote Ischemic Preconditioning | Arm Label: CONTROL; Type: SHAM_COMPARATOR; Interventions: Procedure: Control/sham procedure (blood pressure cuff) | Intervention Type: PROCEDURE; Name: Remote Ischemic Preconditioning; Assigned to Arm(s): RIPC | Intervention Type: PROCEDURE; Name: Control/sham procedure (blood pressure cuff); Assigned to Arm(s): CONTROL
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Bispectral index protocol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: End tidal anesthetic gas-guided | Intervention Type: BEHAVIORAL; Name: Bispectral index protocol; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: End tidal anesthetic gas-guided; Assigned to Arm(s): 2
C: Arm Label: multifaceted prevention program; Type: EXPERIMENTAL; Interventions: Behavioral: Multifaceted prevention program HELP(Hospital Elder Life Program) | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multifaceted prevention program HELP(Hospital Elder Life Program); Assigned to Arm(s): multifaceted prevention program
D: Arm Label: Drug: Xenon; Type: EXPERIMENTAL; Interventions: Drug: Xenon | Arm Label: Drug: Sevoflurane; Type: ACTIVE_COMPARATOR; Interventions: Drug: sevoflurane | Intervention Type: DRUG; Name: Xenon; Assigned to Arm(s): Drug: Xenon | Intervention Type: DRUG; Name: sevoflurane; Assigned to Arm(s): Drug: Sevoflurane

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomised, Double-blind, Parallel-group Phase III Study to Assess High Dose Esomeprazole Na i.v. Treatment (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour Administered for 72 Hours) for Prevention of Rebleeding
Brief Summary: To describe the rate of clinically significant rebleeding during 72 hours continuous i.v. infusion of high dose esomeprazole Na in patients in China with primary successful endoscopic haemostatic therapy of a bleeding peptic ulcer, with cimetidine i.v. in


Options:
A: Arm Label: Double oral dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) | Arm Label: Regular oral dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) | Intervention Type: DRUG; Name: esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden); Assigned to Arm(s): Control group, Double oral dose, Regular oral dose
B: Intervention Type: DRUG; Name: Omeprazole; Assigned to Arm(s): N/A
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omeprazole | Intervention Type: DRUG; Name: Omeprazole; Assigned to Arm(s): 2
D: Arm Label: Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Esomeprazole Na, Drug: Esomeprazole Mg | Arm Label: Cimetidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cimetidine | Intervention Type: DRUG; Name: Esomeprazole Na; Assigned to Arm(s): Esomeprazole | Intervention Type: DRUG; Name: Cimetidine; Assigned to Arm(s): Cimetidine | Intervention Type: DRUG; Name: Esomeprazole Mg; Assigned to Arm(s): Esomeprazole

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Protocol is intended to characterize the overall safety and tolerability of eculizumab in this population.


Options:
A: Arm Label: Ravulizumab; Type: EXPERIMENTAL; Interventions: Biological: Ravulizumab | Intervention Type: BIOLOGICAL; Name: Ravulizumab; Assigned to Arm(s): Ravulizumab
B: Arm Label: Ravulizumab; Type: EXPERIMENTAL; Interventions: Biological: Ravulizumab | Intervention Type: BIOLOGICAL; Name: Ravulizumab; Assigned to Arm(s): Ravulizumab
C: Arm Label: ECULIZUMAB; Type: OTHER; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): ECULIZUMAB
D: Arm Label: eculizumab; Type: EXPERIMENTAL; Interventions: Drug: eculizumab | Intervention Type: DRUG; Name: eculizumab; Assigned to Arm(s): eculizumab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Topical Oil Application on Trans-Epidermal Water Loss in Preterm Infants - A Randomized Clinical Trail
Brief Summary: The skin of newborn infants is immature and ineffective as a barrier. Preterm skin exhibits even more vulnerability to the environment due to poor self regulatory heat mechanisms, paucity of fatty tissue and its thinness. Most preterm babies lose up to 13% of their weight as water loss from their skin during the first week of life. Many strategies have been utilized by neonatologists to decrease this water loss. Edible coconut oil application on the skin acts as a non permeable barrier and can help in achieving this. Hence the investigators decided to undertake this study to objectively assess the reduction in water loss from skin after oil application.


Options:
A: Arm Label: Coconut Oil Application; Type: EXPERIMENTAL; Interventions: Procedure: Coconut Oil Application | Arm Label: No Oil Application; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Coconut Oil Application; Assigned to Arm(s): Coconut Oil Application
B: Arm Label: Twice daily use treatment with EpiCeram; Type: ACTIVE_COMPARATOR; Interventions: Drug: EpiCeram | Arm Label: Standard skin care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: EpiCeram; Assigned to Arm(s): Twice daily use treatment with EpiCeram
C: Arm Label: Observation only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Food intervention; Type: EXPERIMENTAL; Interventions: Other: Food intervention | Arm Label: Skin care; Type: EXPERIMENTAL; Interventions: Other: Skin care | Arm Label: Food intervention and skin care; Type: EXPERIMENTAL; Interventions: Other: Food intervention, Other: Skin care | Intervention Type: OTHER; Name: Food intervention; Assigned to Arm(s): Food intervention, Food intervention and skin care | Intervention Type: OTHER; Name: Skin care; Assigned to Arm(s): Food intervention and skin care, Skin care
D: Arm Label: Topical Emollient; Type: EXPERIMENTAL; Interventions: Other: Topical Emollient | Arm Label: Routine Skin Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Topical Emollient; Assigned to Arm(s): Topical Emollient

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Topical Oil Application on Trans-Epidermal Water Loss in Preterm Infants - A Randomized Clinical Trail
Brief Summary: The skin of newborn infants is immature and ineffective as a barrier. Preterm skin exhibits even more vulnerability to the environment due to poor self regulatory heat mechanisms, paucity of fatty tissue and its thinness. Most preterm babies lose up to 13% of their weight as water loss from their skin during the first week of life. Many strategies have been utilized by neonatologists to decrease this water loss. Edible coconut oil application on the skin acts as a non permeable barrier and can help in achieving this. Hence the investigators decided to undertake this study to objectively assess the reduction in water loss from skin after oil application.


Options:
A: Arm Label: Bathing within 24-48; Type: EXPERIMENTAL; Interventions: Procedure: Bathing | Arm Label: Bathing within 48-72; Type: EXPERIMENTAL; Interventions: Procedure: Bathing | Intervention Type: PROCEDURE; Name: Bathing; Assigned to Arm(s): Bathing within 24-48, Bathing within 48-72
B: Arm Label: Coconut Oil Application; Type: EXPERIMENTAL; Interventions: Procedure: Coconut Oil Application | Arm Label: No Oil Application; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Coconut Oil Application; Assigned to Arm(s): Coconut Oil Application
C: Arm Label: Twice daily use treatment with EpiCeram; Type: ACTIVE_COMPARATOR; Interventions: Drug: EpiCeram | Arm Label: Standard skin care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: EpiCeram; Assigned to Arm(s): Twice daily use treatment with EpiCeram
D: Arm Label: Daily Emollient; Type: EXPERIMENTAL; Interventions: Other: Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream | Arm Label: Natural Skin; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream; Assigned to Arm(s): Daily Emollient

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Acute kidney injury (AKI) frequently occurs after cardiac surgery using cardiopulmonary bypass (CPB). Recombinant human erythropoietin (rHuEPO) is known to provide organ protection against ischemia-reperfusion injury through its anti-inflammatory properties. The aim of the present study was to investigate the effect of a single preoperative bolus of EPO on the incidence of AKI following complex valvular heart surgery in a randomized, controlled and double-blind trial.


Options:
A: Arm Label: Darbepoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Dose Escalation Safety; Type: PLACEBO_COMPARATOR; Interventions: Drug: Epoetin alfa | Arm Label: Single Dose Efficacy; Type: PLACEBO_COMPARATOR; Interventions: Drug: Epoetin alfa | Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): Dose Escalation Safety, Single Dose Efficacy
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erythropoietin | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Erythropoietin; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): B
D: Arm Label: EPO group; Type: EXPERIMENTAL; Interventions: Drug: EPO group | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: EPO group; Assigned to Arm(s): EPO group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Brief Summary: The purpose of this study is to evaluate the safety and tolerability as well as the pharmacodynamic effects of multiple doses of AVX-470 administered orally in patients with active ulcerative colitis.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Golimumab 1 milligram (mg) per kilogram (kg); Type: EXPERIMENTAL; Interventions: Drug: Golimumab 1 mg per kg | Arm Label: Golimumab 2 mg per kg; Type: EXPERIMENTAL; Interventions: Drug: Golimumab 2 mg per kg | Arm Label: Golimumab 4 mg per kg; Type: EXPERIMENTAL; Interventions: Drug: Golimumab 4 mg per kg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Golimumab 1 mg per kg; Assigned to Arm(s): Golimumab 1 milligram (mg) per kilogram (kg) | Intervention Type: DRUG; Name: Golimumab 2 mg per kg; Assigned to Arm(s): Golimumab 2 mg per kg | Intervention Type: DRUG; Name: Golimumab 4 mg per kg; Assigned to Arm(s): Golimumab 4 mg per kg
B: Arm Label: AVX 470; Type: ACTIVE_COMPARATOR; Interventions: Drug: AVX 470 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AVX 470; Assigned to Arm(s): AVX 470 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: rhuMAb Beta7; Type: EXPERIMENTAL; Interventions: Drug: rhuMAb Beta7 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: rhuMAb Beta7; Assigned to Arm(s): rhuMAb Beta7
D: Arm Label: 1 (i); Type: ACTIVE_COMPARATOR; Interventions: Drug: Rituximab | Arm Label: 2 (ii); Type: PLACEBO_COMPARATOR; Interventions: Drug: Rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): 1 (i), 2 (ii)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of 3 Months of Controlled Whole Body Vibrations With Low Exposure Period on the Risk of Falls Among Nursing Home Residents
Brief Summary: Tiredness, lack of motivation and low compliance can be observed in nursing home residents during the practice of physical activity. Because exercises should not be too vigorous, whole body vibration could potentially be an effective alternative.

The objective of this randomized controlled trial is to assess the impact of 3-month training by whole body vibration on the risk of falls among nursing home residents.

Patients were randomized into two groups: the whole body vibration group which received 3 training sessions every week composed of 5 series of only 15 seconds of vibrations at 30 Hz intensity and a control group with normal daily life for the whole study period.

The impact of this training on the risk of falls was assessed blindly by three tests: the Tinetti Test, the Timed Up and Go test and a quantitative evaluation of a 10-second walk performed with a tri-axial accelerometer.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Fall Prevention Tool Kit prototype using a randomized design | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Fall Prevention Tool Kit prototype using a randomized design; Assigned to Arm(s): 1
B: Arm Label: Person-centered Care; Type: EXPERIMENTAL; Interventions: Other: Person-centered Care, Other: Optimised Treatment | Arm Label: Optimised Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Optimised Treatment | Intervention Type: OTHER; Name: Person-centered Care; Assigned to Arm(s): Person-centered Care | Intervention Type: OTHER; Name: Optimised Treatment; Assigned to Arm(s): Optimised Treatment, Person-centered Care
C: Arm Label: Whole Body Vibration Group; Type: EXPERIMENTAL; Interventions: Device: Vibrosphère device | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Vibrosphère device; Assigned to Arm(s): Whole Body Vibration Group
D: Arm Label: Multidisciplinary medication review; Type: EXPERIMENTAL; Interventions: Procedure: Multidisciplinary medication review | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Multidisciplinary medication review; Assigned to Arm(s): Multidisciplinary medication review

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety of Intravenous Transplantation of Bone Marrow Derived Mesenchymal Stem Cell in Patients With ALS
Brief Summary: ALS is a debilitating disease with varied etiology characterized by rapidly progressive weakness, muscle atrophy and fasciculations, muscle spasticity, difficulty speaking (dysarthria), difficulty swallowing (dysphagia), and difficulty breathing (dyspnea). ALS is the most common of the five motor neuron diseases.Riluzole (Rilutek) is the only treatment that has been found to improve survival but only to a modest extent. It lengthens survival by several months, and may have a greater survival benefit for those with a bulbar onset. It also extends the time before a person needs ventilation support.Stem cell transplantation is a new hopeful way to improve the patients conditions and reduce the period of disabilities.


Options:
A: Arm Label: MSC-NTF; Type: EXPERIMENTAL; Interventions: Biological: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF | Intervention Type: BIOLOGICAL; Name: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF; Assigned to Arm(s): MSC-NTF
B: Arm Label: MSC-NTF cells IM; Type: EXPERIMENTAL; Interventions: Biological: MSC-NTF cells transplantation (IM) | Arm Label: MSC-NTF cells IT; Type: EXPERIMENTAL; Interventions: Biological: MSC-NTF cells transplantation (IT) | Intervention Type: BIOLOGICAL; Name: MSC-NTF cells transplantation (IM); Assigned to Arm(s): MSC-NTF cells IM | Intervention Type: BIOLOGICAL; Name: MSC-NTF cells transplantation (IT); Assigned to Arm(s): MSC-NTF cells IT
C: Arm Label: stem cell reciepient; Type: EXPERIMENTAL; Interventions: Biological: intra venous injection of stem cell | Intervention Type: BIOLOGICAL; Name: intra venous injection of stem cell; Assigned to Arm(s): stem cell reciepient
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: MCI-186, Drug: MCI-186 in open label phase | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: MCI-186 in open label phase | Intervention Type: DRUG; Name: MCI-186; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: MCI-186 in open label phase; Assigned to Arm(s): Arm 1, Arm 2

Answer: C